Marking the third year, the Time To Go™ campaign features Holly Robinson Peete in conversation with real-life patients sharing about their experiences managing the disruptive condition of OAB...

Nuvisertib (TP-3654), an oral investigational highly selective PIM1 kinase inhibitor, is being evaluated in a Phase 1/2 study in patients with relapsed/refractory myelofibrosis Enzomenib...

MARLBOROUGH, Mass., September 23, 2024 – Sumitomo Pharma America, Inc. (SMPA) today announced that Kenton Stewart, Senior Vice President, Head of Sales and Market Access, has been promoted to...

– DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with a mixed lineage leukemia...

– DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia – MARLBOROUGH, Mass., June 14, 2024 /PRNewswire